ストックスクリーナーアプリを入手
14.14
2.15%
-0.31
前日終値:
$14.45
開ける：
$14.32
24時間の取引高:
1.01M
Relative Volume:
0.68
時価総額：
$2.01B
収益：
-
当期純損益:
$-45.61M
株価収益率:
-43.71
EPS:
-0.3235
ネットキャッシュフロー:
$-45.40M
1週間 パフォーマンス:
+0.07%
1か月 パフォーマンス:
+2.32%
6か月 パフォーマンス:
+7.20%
1年 パフォーマンス:
+122.33%
1日の値動き範囲:
$14.11
$14.56
1週間の範囲:
$14.03
$14.75
52週間の値動き範囲:
$5.3801
$16.12
Trevi Therapeutics Inc Stock (TRVI) Company Profile
名前
Trevi Therapeutics Inc
セクター
電話
203-304-2499
住所
195 CHURCH STREET, NEW HAVEN, CT
Compare TRVI vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TRVI
Trevi Therapeutics Inc
|
14.14 | 2.05B | 0 | -45.61M | -45.40M | -0.3235 |
VRTX
Vertex Pharmaceuticals Inc
|
447.54 | 113.70B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.78 | 65.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
835.99 | 52.14B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.98 | 40.73B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.48 | 32.87B | 742.00K | -1.37B | -1.07B | -7.0731 |
Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-13 | 開始されました | Leerink Partners | Outperform |
| 2025-08-21 | 開始されました | Morgan Stanley | Overweight |
| 2025-07-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-05-28 | 開始されました | H.C. Wainwright | Buy |
| 2025-03-10 | 繰り返されました | Needham | Buy |
| 2025-03-10 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2024-12-12 | 繰り返されました | H.C. Wainwright | Buy |
| 2024-09-09 | 再開されました | Leerink Partners | Outperform |
| 2024-08-30 | 開始されました | H.C. Wainwright | Buy |
| 2024-08-30 | 開始されました | Raymond James | Outperform |
| 2024-06-13 | 開始されました | Rodman & Renshaw | Buy |
| 2023-04-12 | 開始されました | B. Riley Securities | Buy |
| 2022-11-22 | 開始されました | SVB Leerink | Outperform |
| 2019-06-03 | 開始されました | BMO Capital Markets | Outperform |
| 2019-06-03 | 開始されました | Needham | Buy |
| 2019-06-03 | 開始されました | SVB Leerink | Outperform |
| 2019-06-03 | 開始されました | Stifel | Buy |
すべてを表示
Trevi Therapeutics Inc (TRVI) 最新ニュース
Cantor Fitzgerald Initiates Coverage of Trevi Therapeutics (TRVI) with Overweight Recommendation - MSN
Clear Street Maintains Trevi Therapeutics (TRVI) Buy Recommendation - MSN
Trevi Therapeutics Announces Proposed Public Offering of Common Stock - Quantisnow
TRVI Reiterated by Needham -- Price Target Maintained at $23 - GuruFocus
TRVI News | TREVI THERAPEUTICS INC (NASDAQ:TRVI) - ChartMill
Trevi Therapeutics stock (US89357P1049): short interest remains high as Wall Street targets signal u - AD HOC NEWS
Trevi Therapeutics maps Haduvio chronic cough push, sees cash runway into 2030 - MSN
Trevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates - GuruFocus
Trevi Therapeutics, Inc. (TRVI) Analyst/Investor DaySlideshow (NASDAQ:TRVI) 2026-05-15 - Seeking Alpha
Trevi Therapeutics, Inc.Common Stock (Nasdaq:TRVI) Stock Quote - FinancialContent
Trevi Therapeutics Inc at Bank of America Global Healthcare Conference Transcript - GuruFocus
TradingKey - TradingKey
Revenue per share of Trevi Therapeutics, Inc. – NASDAQ:TRVI - TradingView
TRVI Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Nan Fung Trinity HK Ltd. Boosts Holdings in Trevi Therapeutics, Inc. $TRVI - MarketBeat
F m Investments LLC Buys New Position in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Comerica Bank Has $1.04 Million Stake in Trevi Therapeutics, Inc. $TRVI - MarketBeat
Trevi Therapeutics Maps Haduvio Chronic Cough Push, Sees Cash Runway Into 2030 - sharewise.com
Trevi Therapeutics (NASDAQ:TRVI) Stock Rating Lowered by Wall Street Zen - MarketBeat
Oppenheimer Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Maintains Target Price $24 - 富途牛牛
Stifel Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Raises Target Price to $30 - 富途牛牛
Equities Analysts Offer Predictions for TRVI Q2 Earnings - MarketBeat
Trevi Therapeutics, Inc. (TRVI) Stock Analysis: A Biotech With 59.82% Potential Upside - DirectorsTalk Interviews
NEA stake in Trevi now 10.5% on share increase (TRVI) - Stock Titan
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q1 2026 Earnings Call Transcript - Insider Monkey
Research Analysts Set Expectations for TRVI FY2030 Earnings - MarketBeat
Analysts Are Bullish on Top Healthcare Stocks: Trevi Therapeutics (TRVI), EyePoint Pharmaceuticals (EYPT) - The Globe and Mail
Trevi Therapeutics, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Why Trevi Therapeutics (TRVI) Is Up 5.9% After Extending Its Cash Runway Into 2030 - Yahoo Finance
FMR LLC shows 6.3% stake in Trevi Therapeutics (NASDAQ: TRVI) - Stock Titan
B. Riley Adjusts Trevi Therapeutics Price Target to $21 From $16, Maintains Buy Rating - marketscreener.com
Trevi Therapeutics (NASDAQ:TRVI) Price Target Lowered to $23.00 at Needham & Company LLC - MarketBeat
HC Wainwright Reaffirms Buy Rating for Trevi Therapeutics (NASDAQ:TRVI) - MarketBeat
Trevi Therapeutics Q1 2026 Earnings Call Transcript - MarketBeat
MSN Money - MSN
Stifel reiterates Buy rating on Trevi Therapeutics stock at $18 - Investing.com
Stifel reiterates Buy rating on Trevi Therapeutics stock at $18 By Investing.com - Investing.com Canada
Trevi Therapeutics Q1 Earnings Call Highlights - MarketBeat
Trevi Therapeutics : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q) - marketscreener.com
Earnings call transcript: Trevi Therapeutics Q1 2026 highlights cash boost and clinical progress - Investing.com UK
TRVI: Cash runway into 2030 supports multiple advancing chronic cough trials and new patent coverage - TradingView
Earnings call transcript: Trevi Therapeutics Q1 2026 highlights cash boost and clinical progress By Investing.com - Investing.com South Africa
Trevi Therapeutics Q1 net loss widens as R&D costs rise - TradingView
Trevi Therapeutics (NASDAQ:TRVI) Releases Quarterly Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
Q1 2026 Trevi Therapeutics Inc Earnings Call Transcript - GuruFocus
Trevi Therapeutics (NASDAQ: TRVI) raises $162M, funds cough trials - Stock Titan
Trevi Therapeutics (NASDAQ: TRVI) widens Q1 loss and raises $173M - Stock Titan
Fresh $162M gives Trevi runway into 2030 ahead of Phase 3 cough trials - Stock Titan
Trevi Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
BRIEF-Trevi Therapeutics Q1 Net Income USD -13.192 Million - TradingView
Trevi Therapeutics Inc (TRVI) 財務データ
収益
当期純利益
現金流量
EPS
0.37%
1.35%
大文字化:
|
ボリューム (24 時間):